ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: Although conventional chemotherapy regimens are utilized as front-line therapy, they are associated with a 5-year OS of 14% to 35% for the most common PTCL histologies, excluding ALK-positive ALCL, which is traditionally associated with a more favorable prognosis (5-yr OS of 70% to 79%; Poole, 2014; Sharbnik et al., 2013).